A Phase I Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Inclusion Criteria

Individuals may be eligible for this study if they are 18 years of age or older and:

- Have one of the following types of T-Cell Lymphoproliferative disorders such as
Cutaneous T-cell Lymphoma (CTCL), Peripheral T-cell Lymphoma (PCTL), Large Cell
Lymphoma (LGL), or Adult T-cell Lymphoma (ATL). Patients should have disease that is
resistant or refractory to the front-line therapy, except ATL patients for whom there
is no standard therapy.

- At least 30% of tumor cells must be CD2 positive.

- Karnofsky Performance status of greater than or equal to 70% (able to care for
themselves; but unable to carry on normal activity or to do active work).

- At least 3 weeks must have passed since prior systemic cytotoxic chemotherapy,
prolonged or cytolytic steroid therapy or major surgery, and all treatment-related
toxicities must have resolved prior to the first MEDI-507 administration (except
thrombocytopenia).

- Have no prior treatment with MEDI-507.